SCHEMBL31041

SCHEMBL31041

CCCCCNC(=O)Nc1nc2ccccc2s1

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.93
RAB9A P51151 10/20 0.93
SMN1; SMN2 Q16637 6/20 0.93
ALDH1A1 P00352 5/20 0.62
NFKB1 P19838 2/20 0.62
NFKB2 Q00653 2/20 0.62
RELA Q04206 2/20 0.62
CYP1A2 P05177 1/20 0.62
CYP2C19 P33261 1/20 0.62
STAT1 P42224 1/20 0.62
ADORA1 P30542 1/20 0.58
DYRK1A Q13627 1/20 0.58
MAPT P10636 2/20 0.58
MEN1 O00255 1/20 0.58
GAA P10253 1/20 0.58
KMT2A Q03164 1/20 0.58
ACP1 P24666 1/20 0.57
LCK P06239 1/20 0.55
MAPK1 P28482 2/20 0.55
HTT P42858 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6229810 0.96 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL6228337 0.91 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL1842324 0.85 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL2790542 0.85 RAB9A (0.75) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2792307 0.84 NPC1 (0.78) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
Hydrochloric Acid SCHEMBL1844043 0.84 NPC1 (0.97) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL2790525 0.83 NPC1 (0.73) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
Potassium Ion SCHEMBL2788878 0.82 RAB9A (0.72) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL2792818 0.82 NPC1 (0.74) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1
SCHEMBL2791120 0.82 RAB9A (0.74) NPC1RAB9ASMN1; SMN2ALDH1A1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9884839-B2 Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 ELEXOPHARM GMBH (DE) 2018-02-06 US disclosed
EP-3089969-A2 INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASES TYPE 1 AND TYPE 2 Elexopharm GmbH (DE) 2016-11-09 EP disclosed
US-20160318895-A1 Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 ELEXOPHARM GMBH (DE) 2016-11-03 US disclosed
EP-2609089-A1 SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS Universität des Saarlandes (DE) 2013-07-03 EP disclosed
WO-2012025638-A1 SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS Universität des Saarlandes (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318895-A1 Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 HSD17B1, HSD17B2, HSD17B3 NPC1 1349/4885RAB9A 4512/4885SMN1; SMN2 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.